Literature DB >> 3750395

Experience on follow-up of registered rheumatic fever patients in the Zimbabwean Midlands.

S K Lutalo, N Mabonga.   

Abstract

A total of 75 patients with rheumatic fever, 49 acute (ARF) and 26 acute-on-chronic (A-C-RF), registered in the Zimbabwean Midlands during a 7 year period [1973-1980], followed up for 1-12 years where each one had a potential of follow-up of at least 5 years, were reviewed. Their mean age at diagnosis was 13.2 +/- 7.9 (range 3-39) years and 5 of them were over thirty years old. Thirty five percent were followed up regularly although only 20% realised the full potential. 12% of ARF who initially had no carditis, developed it on a recurrence. The disease was more florid among defaulters than among regulars; chronic valvular lesions being clinically established in 2.8 +/- 1.8 (range 1-6) years; chronic heart failure developing in 5.2 years and death occurring in relatively young patients aged 10.9 +/- 3.0 years old. There were more recurrences among defaulters than among regulars (p less than 0.001). The follow-up was better in those with clinically established valvular lesions, worse in the asymptomatic ones and it was unrelated to age or residence. In addition to improving social-economic conditions, parenteral penicillin prophylaxis should be continued until one is at least 40 years old.

Entities:  

Mesh:

Year:  1986        PMID: 3750395

Source DB:  PubMed          Journal:  Trop Geogr Med        ISSN: 0041-3232


  2 in total

1.  Rheumatic fever and rheumatic heart disease among children presenting to two referral hospitals in Harare, Zimbabwe.

Authors:  P Gapu; M Bwakura-Dangarembizi; G Kandawasvika; D Kao; C Bannerman; J Hakim; J A Matenga
Journal:  S Afr Med J       Date:  2015-06-05

Review 2.  A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa.

Authors:  Andre Pascal Kengne; Lucas M Ntyintyane; Bongani M Mayosi
Journal:  Cardiovasc J Afr       Date:  2011-09-07       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.